BioCentury | Feb 3, 2020
Deals

Catalent adds another foothold in new modality manufacturing via takeout of cell therapy provider MaSTherCell

...tumor infiltrating lymphocytes (TILs), and mesenchymal stem cells. MaSTherCell’s investors include Great Point Partners, CDMO Orgenesis Inc....
BioCentury | Apr 26, 2019
Company News

Orgenesis licenses cancer vaccine from Columbia

...Orgenesis gained an exclusive license to a cellular vaccination product platform from Columbia University. Orgenesis Inc. (OTCQX:ORGS...
...a patient’s dendritic cells and macrophages to present the cancer antigens to the immune system. Orgenesis...
...is meant to minimize a cancer cell's ability to mutate and evade immune system response. Orgenesis...
BioCentury | Oct 19, 2018
Financial News

Iovance closes $252M follow-on for Phase II trials

...S.A. to manufacture Iovance's TILs for it's late-stage European trials. MaSTherCell is a subsidiary of Orgenesis Inc....
...to $11.93 Oct. 12. Iovance Biotherapeutics (NASDAQ:IOVA), San Carlos, Calif. Allison Johnson lifileucel (LN-144, contego, TILs) LN-145 Iovance Biotherapeutics Inc. Orgenesis Inc....
BioCentury | Apr 7, 2017
Finance

Fast-growing evergreen

...the second-largest shareholder. The other two exits were cell therapy manufacturer MaSTherCell S.A. , which Orgenesis Inc....
BioCentury | Dec 21, 2015
Financial News

Orgenesis completes private placement of units

...unit comprises a share and a three-year warrant to purchase a share at $0.52. Separately, Orgenesis...
BioCentury | Aug 11, 2014
Company News

Orgenesis management update

...Orgenesis Inc. (OTCQB:ORGS), White Plains, N.Y. Business: Endocrine/Metabolic Hired: Scott Carmer as CEO of Orgenesis’ North...
BioCentury | Jul 14, 2014
Financial News

Orgenesis Inc completes convertible debt financing

Orgenesis Inc . (OTCBB:ORGS), White Plains, N.Y. Business: Endocrine/Metabolic Date completed: 2014-06-25 Type: Convertible debt financing Raised: $1.5 million Shares outstanding prior: 54.2 million Note: The senior secured term loan bears 8% interest, matures on Dec....
BioCentury | Apr 28, 2014
Company News

Orgenesis management update

Orgenesis Inc. (OTCBB:ORGS), White Plains, N.Y. Business: Endocrine/Metabolic Hired: Joseph Tenne as CFO, formerly CFO of Ormat Technologies Inc. WIR Staff...
BioCentury | Jan 14, 2013
Company News

Orgenesis management update

...corporate planning at GlaxoSmithKline plc ; he succeeds Jacob BenArie, who becomes CEO of Orgenesis' Orgenesis...
BioCentury | Apr 16, 2012
Company News

Orgenesis, Tel Hashomer Medical Research Infrastructure and Services Ltd. deal

...autologous insulin-producing cells (AIPC) regeneration technology as a therapy for diabetes under the supervision of Orgenesis...
...Hashomer is eligible for fees, licensing rights and "other considerations." Last month, Tel Hashomer granted Orgenesis...
...be transplanted back into a patient's liver. Details were not disclosed (see BioCentury, March 19). Orgenesis Inc....
Items per page:
1 - 10 of 14
BioCentury | Feb 3, 2020
Deals

Catalent adds another foothold in new modality manufacturing via takeout of cell therapy provider MaSTherCell

...tumor infiltrating lymphocytes (TILs), and mesenchymal stem cells. MaSTherCell’s investors include Great Point Partners, CDMO Orgenesis Inc....
BioCentury | Apr 26, 2019
Company News

Orgenesis licenses cancer vaccine from Columbia

...Orgenesis gained an exclusive license to a cellular vaccination product platform from Columbia University. Orgenesis Inc. (OTCQX:ORGS...
...a patient’s dendritic cells and macrophages to present the cancer antigens to the immune system. Orgenesis...
...is meant to minimize a cancer cell's ability to mutate and evade immune system response. Orgenesis...
BioCentury | Oct 19, 2018
Financial News

Iovance closes $252M follow-on for Phase II trials

...S.A. to manufacture Iovance's TILs for it's late-stage European trials. MaSTherCell is a subsidiary of Orgenesis Inc....
...to $11.93 Oct. 12. Iovance Biotherapeutics (NASDAQ:IOVA), San Carlos, Calif. Allison Johnson lifileucel (LN-144, contego, TILs) LN-145 Iovance Biotherapeutics Inc. Orgenesis Inc....
BioCentury | Apr 7, 2017
Finance

Fast-growing evergreen

...the second-largest shareholder. The other two exits were cell therapy manufacturer MaSTherCell S.A. , which Orgenesis Inc....
BioCentury | Dec 21, 2015
Financial News

Orgenesis completes private placement of units

...unit comprises a share and a three-year warrant to purchase a share at $0.52. Separately, Orgenesis...
BioCentury | Aug 11, 2014
Company News

Orgenesis management update

...Orgenesis Inc. (OTCQB:ORGS), White Plains, N.Y. Business: Endocrine/Metabolic Hired: Scott Carmer as CEO of Orgenesis’ North...
BioCentury | Jul 14, 2014
Financial News

Orgenesis Inc completes convertible debt financing

Orgenesis Inc . (OTCBB:ORGS), White Plains, N.Y. Business: Endocrine/Metabolic Date completed: 2014-06-25 Type: Convertible debt financing Raised: $1.5 million Shares outstanding prior: 54.2 million Note: The senior secured term loan bears 8% interest, matures on Dec....
BioCentury | Apr 28, 2014
Company News

Orgenesis management update

Orgenesis Inc. (OTCBB:ORGS), White Plains, N.Y. Business: Endocrine/Metabolic Hired: Joseph Tenne as CFO, formerly CFO of Ormat Technologies Inc. WIR Staff...
BioCentury | Jan 14, 2013
Company News

Orgenesis management update

...corporate planning at GlaxoSmithKline plc ; he succeeds Jacob BenArie, who becomes CEO of Orgenesis' Orgenesis...
BioCentury | Apr 16, 2012
Company News

Orgenesis, Tel Hashomer Medical Research Infrastructure and Services Ltd. deal

...autologous insulin-producing cells (AIPC) regeneration technology as a therapy for diabetes under the supervision of Orgenesis...
...Hashomer is eligible for fees, licensing rights and "other considerations." Last month, Tel Hashomer granted Orgenesis...
...be transplanted back into a patient's liver. Details were not disclosed (see BioCentury, March 19). Orgenesis Inc....
Items per page:
1 - 10 of 14